Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC

Prostate

Volumn 53, Issue 3, 2002, Pages 183-191

  Neeley, Yilin C ^a   McDonagh, Kevin T ^a   Overwijk, Willem W ^b   Restifo, Nicholas P ^b   Sanda, Martin G ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Immunotherapy; Prostate cancer; T lymphocytes; Tumor antigens; Vaccinia

Indexed keywords

BETA GALACTOSIDASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; IMMUNOREACTIVITY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; BETA-GALACTOSIDASE; CANCER VACCINES; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; VACCINIA VIRUS;

EID: 0036843219     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10136     Document Type: Article

References (33)

1. Cordon-Cardo C, Fuks Z, Drobnjak M, Moreno C, Eisenbach L, Feldman M. Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 1991;51:6372-6380.
2. Eisenbach L, Feldman M. Tumor cell surface determinants in host immunity against metastases. Semin Cancer Biol 1991;2: 179-188.
3. Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM. In vivo priming of two distinct antitumor effector populations: The role of MHC class I expression. J Exp Med 1994;179:1215-1224.
4. Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL. Loss of HLA class I expression in prostate cancer: Implications for immunotherapy. Urology 1995;46:681-687.
5. Bander NH, Yao D, Liu H, Chen YT, Steiner M, Zuccaro W, Moy P. MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate 1997;33: 233-239.
6. Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll DM, Simons JW. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 1995;87:280-285.
7. Smyth MJ, Kelly JM, Baxter AG, Korner H, Sedgwick JD. An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J Exp Med 1998; 188:1611-1619.
8. Smyth MJ, Thia KY, Cretney E, Kelly JM, Snook MB, Forbes CA, Scalzo AA. Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol 1999;162:6658-6662.
9. Mastrangelo MJ, Eisenlohr LC, Gomella L, Lattime EC. Pox-virus vectors: Orphaned and underappreciated. J Clin Invest 2000;105:1031-1034.
10. Lathe R, Kieny MP, Gerlinger P, Clertant P, Guizani I, Cuzin F, Chambon P. Tumour prevention and rejection with recombinant vaccinia. Nature 1987;326:878-880.
11. Baley PA, Yoshida K, Qian W, Sehgal I, Thompson TC. Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. J Steroid Biochem Mol Biol 1995;52: 403-413.
12. Wang M, Chen PW, Bronte V, Rosenberg SA, Restifo NP. Antitumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen. J Immunother Emphasis Tumor Immunol 1995;18:139-146.
13. Chakrabarti S, Sisler JR, Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 1997;23:1094-1097.
14. Smith TL, Jennings R, Potter CW. Use of single radial haemolysis for assessing antibody response to influenza virus vaccines in animals. Med Microbiol Immunol (Berl) 1987;176:329-339.
15. Earl PL, Cooper N, Moss B. Preparation of cell cultures and vaccinia virus stocks. In: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith LA, editors. Current Protocols in Molecular Biology. New York: Greene Publishing Associates and Wiley Interscience; 1991. p 16.16.1-16.16.17.
16. Zijlstra M, Bix M, Simister NE, Loring JM, Raulet DH, Jaenisch R. Beta 2-microglobulin deficient mice lack CD4-8+ cytolytic T cells. Nature 1990;344:742-746.
17. Grusby MJ, Johnson RS, Papaioannou VE, Glimcher LH. Depletion of CD4+ T cells in major histocompatibility complex class II-deficient mice. Science 1991;253:1417-1420.
18. Spriggs MK, Koller BH, Sato T, Morrissey PJ, Fanslow WC, Smithies O, Voice RF, Widmer MB, Maliszewski CR. Beta 2-microglobulin-, CD8+ T-cell-deficient mice survive inoculation with high doses of vaccinia virus and exhibit altered IgG responses. Proc Natl Acad Sci USA 1992;89:6070-6074.
19. Overwijk WW, Surman DR, Tsung K, Restifo NP. Identification of a Kb-restricted CTL epitope of beta-galactosidase: Potential use in development of immunization protocols for "self" antigens. Methods 1997;12:117-123.
20. Griffith TS, Kawakita M, Tian J, Ritchey J, Tartaglia J, Sehgal I, Thompson TC, Zhao W, Ratliff TL. Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses. J Natl Cancer Inst 2000;93:998-1007.
21. Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001;97:192-197.
22. Apasov SG, Sitkovsky MV. Development and antigen specificity of CD8+ cytotoxic T lymphocytes in beta 2-microglobulin-negative, MHC class I-deficient mice in response to immunization with tumor cells. J Immunol 1994;152:2087-2097.
23. Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, Schreiber H. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci USA 1999;96:8633-8638.
24. Surman DR, Dudley ME, Overwijk WW, Restifo NP. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol 2000;164:562-565.
25. Greenberg PD, Kern DE, Cheever MA. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med 1985;161:1122-1134.
26. Kahn M, Sugawara H, McGowan P, Okuno K, Nagoya S, Hellstrom KE, Hellstrom I, Greenberg P. CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J Immunol 1991;146:3235-3241.
27. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998;187:693-702.
28. Reilly RT, Machiels JP, Emens LA, Ercolini AM, Okoye FI, Lei RY, Weintraub D, Jaffee EM. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res 2001;61:880-883.
29. Hahn S, Gehri R, Erb P. Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol Rev 1995;146:57-79.
30. Katsumoto Y, Monden T, Takeda T, Haba A, Ito Y, Wakasugi E, Wakasugi T, Sekimoto M, Kobayashi T, Shiozaki H, Shimano T, Monden M. Analysis of cytotoxic activity of the CD4+ T lymphocytes generated by local immunotherapy. Br J Cancer 1996;73:110-116.
31. Lee HM, Timme TL, Thompson TC. Resistance to lysis by cytotoxic T cells: A dominant effect in metastatic mouse prostate cancer cells. Cancer Res 2000;60:1927-1933.
32. Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res 2001;61:206-214.
33. McNeel DG, Nguyen LD, Ellis WJ, Higano CS, Lange PH, Disis ML. Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. Prostate 2001;47:222-229.